Kurt Pii

Title: Kurt Pii - Innovator in Monoclonal Antibody Development

Introduction

Kurt Pii is a notable inventor based in Farum, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions that have the potential to impact therapeutic applications.

Latest Patents

Kurt Pii holds a patent for the PAX 5 monoclonal antibody. This invention relates to anti-human PAX 5 antibodies capable of binding to one or more epitopes located within the C-terminal regulatory domain of PAX 5. Specifically, the patent describes an antibody, antigen binding fragment, or recombinant protein that can specifically bind to an epitope within the C-terminal fragment of the human PAX 5 protein. The epitope comprises from 3 to 17 amino acid residues of the sequence GSPYYYSAAARGAAPPA (SEQ ID NO:2). The invention also includes immunogenic peptide sequences for the production of these antibodies, along with diagnostic and therapeutic applications that utilize these antibodies and their formulations. Kurt Pii has 1 patent to his name.

Career Highlights

Kurt Pii is associated with Dako Denmark A/S, a company known for its advancements in cancer diagnostics and antibody development. His role at Dako has allowed him to contribute to groundbreaking research and development in the field of immunology.

Collaborations

Kurt has worked alongside talented colleagues such as Henrik Winther and Jakob O Gjørret. Their collaborative efforts have furthered the research and development of innovative antibody therapies.

Conclusion

Kurt Pii's work in the field of monoclonal antibodies exemplifies the importance of innovation in biotechnology. His contributions have the potential to lead to significant advancements in therapeutic applications.